RHJA
ANIP icon

Rice Hall James & Associates’s ANI Pharmaceuticals ANIP Stock Holding History

Rice Hall James & Associates’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.06M Hold
26,816
– – 0.11% 160
2025
Q4 		$2.12M Sell
26,816
-4,681
-15% -$405K 0.12% 160
2025
Q3 		$2.89M Sell
31,497
-22,482
-42% -$1.83M 0.16% 131
2025
Q2 		$3.52M Sell
53,979
-4,610
-8% -$300K 0.19% 121
2025
Q1 		$3.92M Sell
58,589
-379
-0.6% -$22.6K 0.23% 94
2024
Q4 		$3.26M Sell
58,968
-1,407
-2% -$80.8K 0.18% 130
2024
Q3 		$3.6M Sell
60,375
-297
-0.5% -$18.1K 0.19% 117
2024
Q2 		$3.86M Sell
60,672
-4,162
-6% -$270K 0.23% 96
2024
Q1 		$4.48M Sell
64,834
-86
-0.1% -$5.19K 0.26% 87
2023
Q4 		$3.58M Sell
64,920
-3,283
-5% -$181K 0.21% 113
2023
Q3 		$3.96M Buy
68,203
+20,760
+44% +$1.2M 0.25% 93
2023
Q2 		$2.55M Buy
+47,443
New +$2.1M 0.14% 155
2020
Q3 		– Sell
-27,526
Closed -$890K – 274
2020
Q2 		$890K Sell
27,526
-200
-0.7% -$7.17K 0.04% 216
2020
Q1 		$1.13M Sell
27,726
-217
-0.8% -$11.5K 0.06% 190
2019
Q4 		$1.72M Sell
27,943
-706
-2% -$46.8K 0.06% 187
2019
Q3 		$2.09M Buy
28,649
+2,335
+9% +$175K 0.07% 164
2019
Q2 		$2.16M Sell
26,314
-1,600
-6% -$114K 0.07% 168
2019
Q1 		$1.97M Sell
27,914
-1,225
-4% -$72.1K 0.06% 192
2018
Q4 		$1.31M Buy
29,139
+2,947
+11% +$154K 0.05% 230
2018
Q3 		$1.48M Sell
26,192
-6,186
-19% -$379K 0.05% 227
2018
Q2 		$2.16M Buy
+32,378
New +$2.02M 0.08% 191
2017
Q2 		– Sell
-32,426
Closed -$1.6M – 290
2017
Q1 		$1.6M Sell
32,426
-700
-2% -$39.3K 0.08% 218
2016
Q4 		$2.01M Sell
33,126
-200
-0.6% -$12.2K 0.1% 191
2016
Q3 		$2.21M Buy
+33,326
New +$2.08M 0.12% 164

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Rice Hall James & Associates's ANIP Position: Q1 2026 in Review

Rice Hall James & Associates held its ANI Pharmaceuticals (ANIP) position steady in Q1 2026 at 26,816 shares worth $2.06M. The position accounts for 0.11% of the portfolio, ranked #160.

Rice Hall James & Associates first reported a position in ANIP in Q3 2016 and has held it in 24 quarters since. The position peaked at $4.48M in Q1 2024. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Rice Hall James & Associates held 26,816 shares of ANI Pharmaceuticals worth $2.06M as of Q1 2026.
  • Rice Hall James & Associates left its ANI Pharmaceuticals share count unchanged in Q1 2026.
  • ANI Pharmaceuticals made up 0.11% of Rice Hall James & Associates's portfolio in Q1 2026, its #160 holding.
  • Rice Hall James & Associates first reported a position in ANI Pharmaceuticals in Q3 2016 and has held it in 24 quarters since.
  • Rice Hall James & Associates's ANI Pharmaceuticals position peaked at $4.48M in Q1 2024.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.